Literature DB >> 11991960

Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus.

Elena Chertova1, Julian W Bess, Bruce J Crise, Raymond C Sowder II, Terra M Schaden, Joanne M Hilburn, James A Hoxie, Raoul E Benveniste, Jeffrey D Lifson, Louis E Henderson, Larry O Arthur.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus (SIV) particles typically contain small amounts of the surface envelope protein (SU), and this is widely believed to be due to shedding of SU from mature virions. We purified proteins from HIV-1 and SIV isolates using procedures which allow quantitative measurements of viral protein content and determination of the ratios of gag- and env-encoded proteins in virions. All of the HIV-1 and most of the SIV isolates examined contained low levels of envelope proteins, with Gag:Env ratios of approximately 60:1. Based on an estimate of 1,200 to 2,500 Gag molecules per virion, this corresponds to an average of between 21 and 42 SU molecules, or between 7 and 14 trimers, per particle. In contrast, some SIV isolates contained levels of SU at least 10-fold greater than SU from HIV-1 isolates. Quantification of relative amounts of SU and transmembrane envelope protein (TM) provides a means to assess the impact of SU shedding on virion SU content, since such shedding would be expected to result in a molar excess of TM over SU on virions that had shed SU. With one exception, viruses with sufficient SU and TM to allow quantification were found to have approximately equivalent molar amounts of SU and TM. The quantity of SU associated with virions and the SU:TM ratios were not significantly changed during multiple freeze-thaw cycles or purification through sucrose gradients. Exposure of purified HIV-1 and SIV to temperatures of 55 degrees C or greater for 1 h resulted in loss of most of the SU from the virus but retention of TM. Incubation of purified virus with soluble CD4 at 37 degrees C resulted in no appreciable loss of SU from either SIV or HIV-1. These results indicate that the association of SU and TM on the purified virions studied is quite stable. These findings suggest that incorporation of SU-TM complexes into the viral membrane may be the primary factor determining the quantity of SU associated with SIV and HIV-1 virions, rather than shedding of SU from mature virions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11991960      PMCID: PMC137021          DOI: 10.1128/jvi.76.11.5315-5325.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

1.  Immunogenicity of full length and truncated SIV envelope proteins.

Authors:  A N Vzorov; D Lea-Fox; R W Compans
Journal:  Viral Immunol       Date:  1999       Impact factor: 2.257

2.  Macrophage-tropic and T-cell line-adapted chimeric strains of human immunodeficiency virus type 1 differ in their susceptibilities to neutralization by soluble CD4 at different temperatures.

Authors:  W A O'Brien; S H Mao; Y Cao; J P Moore
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

3.  High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR.

Authors:  M Piatak; M S Saag; L C Yang; S J Clark; J C Kappes; K C Luk; B H Hahn; G M Shaw; J D Lifson
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

4.  Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4.

Authors:  S L Orloff; M S Kennedy; A A Belperron; P J Maddon; J S McDougal
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

5.  Biological, molecular, and structural analysis of a cytopathic variant from a molecularly cloned simian immunodeficiency virus.

Authors:  C C LaBranche; M M Sauter; B S Haggarty; P J Vance; J Romano; T K Hart; P J Bugelski; J A Hoxie
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

6.  Truncation of the cytoplasmic domain of the simian immunodeficiency virus envelope glycoprotein increases env incorporation into particles and fusogenicity and infectivity.

Authors:  K Zingler; D R Littman
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

7.  Strong association of simian immunodeficiency virus (SIVagm) envelope glycoprotein heterodimers: possible role in receptor-mediated activation.

Authors:  J S Allan; E M Whitehead; K Strout; M Short; P Kanda; T K Hart; P J Bugelski
Journal:  AIDS Res Hum Retroviruses       Date:  1992-12       Impact factor: 2.205

8.  Amino acid substitutions in the human immunodeficiency virus type 1 gp120 V3 loop that change viral tropism also alter physical and functional properties of the virion envelope.

Authors:  R L Willey; T S Theodore; M A Martin
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

9.  Physicochemical dissociation of CD4-mediated syncytium formation and shedding of human immunodeficiency virus type 1 gp120.

Authors:  Y K Fu; T K Hart; Z L Jonak; P J Bugelski
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

10.  Increase in soluble CD4 binding to and CD4-induced dissociation of gp120 from virions correlates with infectivity of human immunodeficiency virus type 1.

Authors:  R L Willey; M A Martin; K W Peden
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

View more
  162 in total

1.  The soybean retroelement SIRE1 uses stop codon suppression to express its envelope-like protein.

Authors:  Ericka R Havecker; Daniel F Voytas
Journal:  EMBO Rep       Date:  2003-03       Impact factor: 8.807

2.  The membrane-proximal tyrosine-based sorting signal of human immunodeficiency virus type 1 gp41 is required for optimal viral infectivity.

Authors:  John R Day; Carsten Münk; John C Guatelli
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

3.  Modulation of Env content in virions of simian immunodeficiency virus: correlation with cell surface expression and virion infectivity.

Authors:  Eloísa Yuste; Jacqueline D Reeves; Robert W Doms; Ronald C Desrosiers
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

4.  Femtomole SHAPE reveals regulatory structures in the authentic XMRV RNA genome.

Authors:  Jacob K Grohman; Sumith Kottegoda; Robert J Gorelick; Nancy L Allbritton; Kevin M Weeks
Journal:  J Am Chem Soc       Date:  2011-11-29       Impact factor: 15.419

Review 5.  HIV-1 assembly, budding, and maturation.

Authors:  Wesley I Sundquist; Hans-Georg Kräusslich
Journal:  Cold Spring Harb Perspect Med       Date:  2012-07       Impact factor: 6.915

6.  HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes.

Authors:  Tommy Tong; Ema T Crooks; Keiko Osawa; James M Binley
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

7.  Proteomic and biochemical analysis of purified human immunodeficiency virus type 1 produced from infected monocyte-derived macrophages.

Authors:  Elena Chertova; Oleg Chertov; Lori V Coren; James D Roser; Charles M Trubey; Julian W Bess; Raymond C Sowder; Eugene Barsov; Brian L Hood; Robert J Fisher; Kunio Nagashima; Thomas P Conrads; Timothy D Veenstra; Jeffrey D Lifson; David E Ott
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

8.  Two-dimensional gel-based approaches for the assessment of N-Linked and O-GlcNAc glycosylation in human and simian immunodeficiency viruses.

Authors:  David R M Graham; Megan J Mitsak; Steven T Elliott; Dawn Chen; Stephen A Whelan; Gerald W Hart; Jennifer E Van Eyk
Journal:  Proteomics       Date:  2008-12       Impact factor: 3.984

9.  Ternary complex formation of human immunodeficiency virus type 1 Env, CD4, and chemokine receptor captured as an intermediate of membrane fusion.

Authors:  Samvel R Mkrtchyan; Ruben M Markosyan; Michael T Eadon; John P Moore; Gregory B Melikyan; Fredric S Cohen
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

10.  GSK3732394: a Multi-specific Inhibitor of HIV Entry.

Authors:  David Wensel; Yongnian Sun; Jonathan Davis; Zhufang Li; Sharon Zhang; Thomas McDonagh; David Langley; Tracy Mitchell; Sebastien Tabruyn; Patrick Nef; Mark Cockett; Mark Krystal
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.